Fate Therapeutics issued U.S. patent protecting cellular composition of ProTmune
Fate Therapeutics announced that the USPTO issued a patent covering enhanced hematopoietic stem cell compositions. This newly-issued patent expands the company's intellectual property position covering ex vivo small molecule modulation of hematopoietic stem cells, which includes compositions and methods for enhanced lentiviral transduction and engraftment in the field of hematopoietic cell transplantation. ProTmune is an investigational programmed cellular immunotherapy undergoing clinical development for the prevention of acute graft-versus-host disease and cytomegalovirus infection in patients undergoing allogeneic hematopoietic cell transplantation. The company also has filed corresponding patent applications to seek similar patent protection for its hematopoietic stem cell compositions in key markets including Europe and Japan.